Brief: Polypeptide Group AG - Outlook 2025 Capital Expenditures EUR Around 100 Million
12/08/2025 06:03
Aug 12 (Reuters) - PolyPeptide Group AG PPGN.S: H1 EBITDA EUR 4.434 MILLION H1 CAPEX EUR 46.108 MILLION H1 NET INCOME EUR -26.539 MILLION H1 REVENUE EUR 167.096 MILLION H1 EBIT EUR -13.723 MILLION H1 CASH FLOW FROM OPERATING ACTIVITIES EUR 49.656 MILLION POLYPEPTIDE REVISES ITS GUIDANCE FOR FULL-YEAR 2025 TOWARDS UPPER END OF RANGE 2025 REVENUE GROWTH VERSUS 2024 NOW 13-20% OUTLOOK 2025: EBITDA MARGIN HIGH SINGLE-DIGIT / LOW DOUBLE-DIGIT OUTLOOK 2025: CAPITAL EXPENDITURES EUR AROUND 100 MILLION Source text: ID:nEQ26lrSFa Further company coverage: PPGN.S (Gdansk Newsroom) ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Recent news on PolyPeptide AG
See all newsEurope Research Roundup: Assa Abloy, DHL, Randstad
Brief: Polypeptide Is Said To Shortlist EQT, IDG For Next Bidding Round - Bloomberg News
Brief: Polypeptide Group Says It Is Conducting Review Of Strategic Options
PolyPeptide attracts takeover interest from EQT, KKR, Bloomberg News reports
Media: PolyPeptide Is Said to Attract Takeover Interest From EQT, KKR - Bloomberg News